nach oben

Erschienen in:

01.11.2022 | Dermatomyositis | Fortbildung

Dermatomyositis

Tumorscreening obligatorisch

verfasst von: Prof. Claudia Günther

Erschienen in: Deutsche Dermatologie | Ausgabe 11/2022

Einloggen, um Zugang zu erhalten

Auszug

Die Dermatomyositis beschränkt sich nicht unbedingt nur auf Haut und Muskeln. Erschwerend können eine Beteiligung von Lunge und Herz sowie Tumoren dazukommen. Diagnostisch ist die Bestimmung entsprechender Autoantikörper wesentlich. Die Therapie richtet sich dann nach dem Schweregrad der Erkrankung. …

Wiendl HS, Schmidt J et al. S2k-Leitlinie Myositissyndrome. 2022. AWMF-Reg.-Nr. 030-054

Bendewald MJ et al. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol 2010; 146: 26−30

Furst DE et al. Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve 2012; 45: 676−83

Mendez EP et al. US incidence of juvenile dermatomyositis, 1995−1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003; 49: 300−5

Aussy A et al. Dermatomyositis and Immune-Mediated Necrotizing Myopathies: A Window on Autoimmunity and Cancer. Front Immunol 2017; 8: 992

Fischer K, Günther C. Hautmanifestationen der Dermatomyositis. internistische praxis 2020; 63: 76-86

Dalakas MC. Inflammatory muscle diseases. N Engl J Med 2015; 372: 1734−47

Dugan EM et al. Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatol Online J 2009; 15: 1

Balin SJ et al. Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo Clinic experience with 78 patients, 1996−2009. Arch Dermatol 2012; 148: 455−62

10.

Marton K et al. Evaluation of oral manifestations and masticatory force in patients with polymyositis and dermatomyositis. J Oral Pathol Med 2005; 34: 164−9

11.

Ghali FE et al. Gingival telangiectases: an underappreciated physical sign of juvenile dermatomyositis. Arch Dermatol 1999; 135: 1370−4

12.

Santos-Briz A et al. Dermatomyositis panniculitis: a clinicopathological and immunohistochemical study of 18 cases. J Eur Acad Dermatol Venereol 2018; 32: 1352−9

13.

DeWane ME et al. Dermatomyositis: Clinical features and pathogenesis. J Am Acad Dermatol 2020; 82: 267−81

14.

Mainetti C et al. Cutaneous Manifestations of Dermatomyositis: a Comprehensive Review. Clin Rev Allergy Immunol 2017; 53: 337−56

15.

Hoeltzel MF et al. The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis. Curr Rheumatol Rep 2014; 16: 467

16.

Pearson CM. Polymyositis and dermatomyositis. Bull Rheum Dis 1962; 12: 269−72

17.

Euwer RL, Sontheimer RD. Amyopathic dermatomyositis (dermatomyositis sine myositis). Presentation of six new cases and review of the literature. J Am Acad Dermatol 1991; 24: 959−66

18.

Gerami P et al. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 2006; 54: 597−613

19.

Hundley JL et al. Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life. J Am Acad Dermatol 2006; 54: 217−20

20.

Cavazzana I et al. The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies. Clin Rev Allergy Immunol 2017; 52: 88−98

21.

Sato S et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005; 52: 1571−6

22.

Jayakumar D et al. Manifestations in Idiopathic Inflammatory Myopathies: An Overview. Cardiol Rev 2019; 27: 131−7

23.

Zhang L et al. Cardiac involvement in adult polymyositis or dermatomyositis: a systematic review. Clin Cardiol 2012; 35: 686−91

24.

Schwartz T et al. Cardiac involvement in adult and juvenile idiopathic inflammatory myopathies. RMD Open 2016; 2: e000291

25.

Yang Z e al. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol 2015; 42: 282−91

26.

Hill CL et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001; 357: 96−100

27.

Fischer K, Günther C. Dermatomyositis: State of the art. hautnah dermatologie 2020; 36: 40−4

28.

Lahoria R et al. Microvascular alterations and the role of complement in dermatomyositis. Brain 2016; 139: 1891−1903

29.

Greenberg SA et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005; 57: 664−78

30.

Wenzel J et al. Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. Clin Exp Dermatol 2006; 31: 576−82

31.

Crowson AN, Magro CM. The role of microvascular injury in the pathogenesis of cutaneous lesions of dermatomyositis. Hum Pathol 1996; 27: 15−9

32.

Manfredi A et al. Nailfold capillaroscopic changes in dermatomyositis and polymyositis. Clin Rheumatol 2015; 34: 279−84

33.

Volc-Platzer B. Dermatomyositis-update. Hautarzt 2015; 66: 604−10

34.

Targoff IN. Autoantibodies in polymyositis. Rheum Dis Clin North Am 1992; 18: 455−82

35.

Fiorentino DF et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1 gamma. Arthritis Rheum 2013; 65: 2954−962

36.

Meisterfeld S et al. A chronic recurrent disease course of dermatomyositis is associated with autoantibodies against transcriptional intermediary factor 1-gamma. Br J Dermatol 2017; 177: 590−3

37.

Fiorentino D et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011; 65: 25−34

38.

Kurtzman DJB, Vleugels RA. Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: A concise review with an emphasis on distinctive clinical features. J Am Acad Dermatol 2018; 78: 776−85

39.

Gono T et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford) 2010; 49: 1713−9

40.

Ceribelli A et al. Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/ dermatomyositis. Clin Exp Rheumatol 2014; 32: 891−7

41.

Allenbach Y et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: Study of 121 cases. Neurology 2020; 95: e70−8

42.

Botta A et al. Effect of the [CCTG]n repeat expansion on ZNF9 expression in myotonic dystrophy type II (DM2). Biochim Biophys Acta 2006; 1762: 329−34

43.

Meola G, Cardani R. Myotonic Dystrophy Type 2: An Update on Clinical Aspects, Genetic and Pathomolecular Mechanism. J Neuromuscul Dis 2015; 2: S59−71

44.

Shah M et al. Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis. Arthritis Rheum 2013; 65: 1934−41

45.

Love LA et al. Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. Arthritis Rheum 2009; 60: 2499−504

46.

Okada S et al. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum 2003; 48: 2285−93

47.

Christensen MLet al. Prevalence of Coxsackie B virus antibodies in patients with juvenile dermatomyositis. Arthritis Rheum 1986; 29: 1365−70

48.

Chen Z et al. HLA-DRB1 Alleles as Genetic Risk Factors for the Development of Anti-MDA5 Antibodies in Patients with Dermatomyositis. J Rheumatol 2017; 44: 1389−93

49.

O'Hanlon TP et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) 2006; 85: 111−27

50.

Miller FW et al. Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum 2013; 65: 3239−47

51.

Rothwell S et al. Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Ann Rheum Dis 2016; 75: 1558−66

52.

Wong D et al. Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PLoS One 2012; 7: e29161

53.

Baechler EC et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 2007; 13: 59−68

54.

Huard C et al. Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon beta in dermatomyositis. Br J Dermatol 2017; 176: 1224−30

55.

Bolko L et al. The role of interferons type I, II and III in myositis: A review. Brain Pathol 2021; 31: e12955

56.

Kissel JT et al. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986; 314: 329−34

57.

Worm M et al. S2k-Leitlinie zur Diagnostik und Therapie des kutanen Lupus erythematodes − Teil 2: Therapie, Risikofaktoren und spezielle Fragestellungen. J Dtsch Dermatol Ges 2021; 19: 1371−95

58.

Ueda M et al. Successful treatment of amyopathic dermatomyositis with topical tacrolimus. Br J Dermatol 2003; 148: 595−6

59.

Dalakas MC et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993−2000

60.

Liang J et al. Efficacy and Tolerability of Nintedanib in Idiopathic-Inflammatory-Myopathy-Related Interstitial Lung Disease: A Pilot Study. Front Med (Lausanne) 2021; 8: 626953

61.

Oddis CV et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013; 65: 314−24

62.

Hornung T et al. Remission of recalcitrant dermatomyositis treated with ruxolitinib. N Engl J Med 2014; 371: 2537−8

63.

Fischer K et al. Improvement of cutaneous inflammation and panniculitis in patients with dermatomyositis by the Janus kinase inhibitor baricitinib. Br J Dermatol 2022; 187: 432−5

64.

Wendel S et al. Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib − A report of two cases. J Autoimmun 2019; 100: 131−6

65.

Higgs BW et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-alpha monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 2014; 73: 256−62

Titel: Dermatomyositis
Tumorscreening obligatorisch
verfasst von: Prof. Claudia Günther
Publikationsdatum: 01.11.2022
Verlag: Springer Medizin
Schlagwörter: Dermatomyositis
Erytheme
Erschienen in: Deutsche Dermatologie / Ausgabe 11/2022
Print ISSN: 2731-7692
Elektronische ISSN: 2731-7706
DOI: https://doi.org/10.1007/s15011-022-5635-1

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

22.04.2024 | DGIM 2024 | Nachrichten

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Tumorscreening obligatorisch

Auszug

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Dermatologie

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2022

"Den schlafenden Riesen Ambulantisierung wecken"

Bereitschaft zur Niederlassung steigt

Oxidativer Stress und Inflammationsprozesse

Industrieforum

Sparen mit dem Chaos Computer Club

Berufspolitische Herausforderungen in Zeiten des Umbruchs

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Dermatologie